Randomized Trial of Web-Delivered Acceptance Therapy for Smoking Cessation (WebQuit)

Smoking Clinical Trial

Official title:

Randomized Trial of Web-Delivered Acceptance Therapy for Smoking Cessation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01812278
• Other study ID #: 7859
• Secondary ID: NCI-2019-06975R0
• Status: Completed
• Phase: N/A
• Start date: March 24, 2014
• Est. completion date: December 31, 2019

Study information

• Verified date: December 2019
• Source: Fred Hutchinson Cancer Research Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to determine whether the ACT website provides higher quit rates than a current standard smoking cessation website.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2637
• Est. completion date: December 31, 2019
• Est. primary completion date: October 26, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• age 18 or older

• smokes at least five cigarettes daily for at least past 12 months

• wants to quit in next 30 days

• willing to be randomly assigned to either group

• resides in US

• has at least weekly access to a high speed Internet connection and email

• willing and able to read in English

• not participating in other smoking cessation interventions (including our other intervention studies

• has never used the Smokefree.gov website

• willing to complete all three follow-up surveys

• provide email, phone, and mailing address

• provide contact information for two collaterals (e.g., relatives).

• does not have family, friends, or other household members participating

Exclusion Criteria:

• The exclusion criteria are the opposite of the inclusion criteria above.

Related Conditions & MeSH terms

• Smoking

Intervention

Behavioral:
• ACT

• CBT

Locations

Country	Name	City	State
United States	Fred Hutchinson Cancer Research Center	Seattle	Washington

Sponsors (4)

Lead Sponsor	Collaborator
Fred Hutchinson Cancer Research Center	Kaiser Permanente, National Cancer Institute (NCI), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	30-day point prevalence abstinence	No smoking in the past 30 days, as reported 12 month post treatment.	12 month post randomization
Secondary	7-day, 24-hour, and 30-day point prevalence quit rates	12 months: 24-hour and 7-day point prevalence quit rates. 3 and 6 months: 24-hour, 7-day, and 30-day point prevalence quit rates. Across 3, 6, and 12 month timepoints, the repeated 30-day point prevalence abstinence.	3 months, 6 months, and 12 months post treatment